Drugs Made In America Acquisition II Corp. has announced the pricing of its $500 million initial public offering, consisting of 50 million units at $10.00 per unit. The units are listed on the Nasdaq Global Market under the ticker symbol "DMIIU" starting September 25, 2025. Each unit includes one ordinary share and one right to receive one-tenth of an ordinary share upon the completion of an initial business combination. Once separated, the ordinary shares and rights are expected to trade under "DMII" and "DMIIR," respectively. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093224), on September 29, 2025, and is solely responsible for the information contained therein.